4 Needs context
Lovaza contains EPA and DHA in an approximate ratio of 2:1 to 3:2.
"It's about two parts EPA to one part DHA, roughly. Or three to two." (said at 0:13:28)
Lovaza (prescription omega-3-acid ethyl esters, also marketed as Omacor) contains 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) per 1-gram capsule. This yields an EPA-to-DHA ratio of approximately 1.24:1 (or roughly 5:4). The speaker's estimate of 'three to two' (1.5:1) is a close approximation, whereas 'two to one' (2:1) overstates the proportion of EPA relative to DHA.
- context: Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty a… (The American journal of cardiology 2006) · cited 123x in the literature
"Omacor (omega-3-acid ethyl esters; Reliant Pharmaceuticals, Inc., Liberty Corner, NJ) is a highly purified, prescription omega-3 fatty acid formulation with high concentrations of eicosapentaenoic acid (EPA) (465 mg) and docosahexaenoic acid (DHA) (375 mg) in each 1-g capsule, along with 4 mg (6 IU) of vitamin E." (abstract, introduction, passage verified)
pubmedfull study (doi) - context: Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides. (Postgraduate medicine 2009) · cited 28x in the literature
"Clinical trials in adult patients with VHTGs show that four 1 g capsules of prescription omega-3 fatty acids, which contain 465 mg of EPA and 375 mg of DHA per capsule, can effectively decrease TG levels by up to 45%, and is generally well tolerated." (abstract, results, passage verified)
pubmedfull study (doi)
In a metabolic ward feeding study of healthy volunteers consuming high-dose salmon oil for one month, average serum triglyceride levels decreased by 25%, from 100 mg/dL to 75 mg/dL.
"Well, they're—I mean, these were normal, healthy volunteers, so their average triglyceride level was 100. It went all the way down to 75. But statistically—I mean, it's a 25% reduction" (said at 0:05:04)
In a controlled 4-week dietary feeding study in healthy volunteers comparing a salmon oil diet to saturated fat and vegetable oil diets (Harris et al., 1983), the salmon oil diet significantly reduced plasma triglyceride levels from 77 mg/dL to 48 mg/dL (a ~38% reduction, p < 0.005), rather than from 100 mg/dL to 75 mg/dL (a 25% reduction) as stated by the speaker. The overall finding that a high-dose salmon oil diet substantially lowers triglycerides in healthy normolipidemic volunteers is accurate, though the specific baseline and post-diet values were slightly misremembered.
Lovaza received FDA approval to lower triglycerides by about 20% specifically in patients with baseline triglyceride levels exceeding 500 mg/dL.
"And that when it all began with Lovaza, they said you lower, "Well, look, we can lower triglycerides by 20%," and that was enough to get them an indication for people with triglycerides over 500, that's the limitation." (said at 1:06:10)
The claim accurately states the FDA approval threshold for prescription omega-3-acid ethyl esters (Lovaza, originally approved as Omacor): it was approved specifically as an adjunct to diet in adult patients with severe hypertriglyceridemia defined as baseline triglyceride levels of ≥500 mg/dL. However, pivotal clinical trials supporting this approval demonstrated median triglyceride reductions of approximately 45% at the approved dose of 4 g/day, rather than 20%.
A red blood cell DHA level of 3% or lower is associated with high risk for preterm birth, whereas levels above 5% are not high risk.
"from the risk factors we can control, if you're down at 3%, that's the high-risk group for preterm birth. Over 5% is not a problem." (said at 1:40:53)
Large randomized clinical trials and biomarker analyses (such as the ORIP trial and subsequent biomarker translation studies) show that low maternal omega-3/DHA status in early pregnancy is strongly associated with an increased risk of early preterm birth (<34 weeks), and that women with low baseline levels benefit most from supplementation. However, the precise numerical thresholds described by the speaker (3% or lower defining high risk and above 5% defining replete/safe status) correspond to whole blood or serum/plasma total omega-3 percentages (such as whole blood cut-points ≤4.1% or <4.2% for low status and >4.9% for replete status, or plasma/serum cut-points of <3.7% and >4.3%), rather than red blood cell (RBC) total fatty acid levels. When translated to RBC total fatty acids, the corresponding established cut-points for low and replete status are <7.3% and >8.1%, respectively.
- context: Omega-3 fatty acid supplementation in pregnancy-baseline omega-3 status and early preterm … (BJOG : an international journal of obstetrics and gynaecology 2020) · cited 101x in the literature
"A low total omega-3 PUFA status in early pregnancy was associated with a higher risk of early preterm birth. Among women with a total omega-3 status ≤4.1% of total fatty acids, omega-3 supplementation substantially reduced the risk of early preterm birth compared with control (0.73 versus 3.16%; relative risk = 0.23, 95% confidence interval [CI] 0.07-0.79). Conversely, women with higher total omega-3 status in early pregnancy were at lower risk of early preterm birth." (abstract, results, passage verified)
pubmedfull study (doi) - context: Translating n-3 polyunsaturated fatty acid status from whole blood to plasma and red blood… (Prostaglandins, leukotrienes, and essential fatty acids 2022) · cited 14x in the literature
"Using the conversion equations, established cut-points for low and replete n-3 status in whole blood (<4.2% and >4.9% of total fatty acids) converted to <3.7% and >4.3% of plasma total fatty acids, and to <7.3% and >8.1% of RBC total fatty acids." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.